What will the prevailing sentiment be about Rapamycin as a longevity drug in 2028?
Plus
5
Ṁ2672028
1D
1W
1M
ALL
11%
Wonder-drug: Most adults should consider it
22%
Valuable but imperfect: Some healthy adults should consider it, but there are major drawbacks
24%
Unproven but promising: Too early to tell
30%
Ineffective: Any benefits are too small to be worth the drawbacks
12%
Harmful/scandalous: Clear serious drawbacks that last beyond cessation of treatment
I'll post a proposed resolution here for discussion at least one week before resolving. May resolve to a mixture of up to two different choices in borderline cases.
If there's any substantial disagreement, I'll ask a popular LLM-style chatbot to select a resolution based on the title of the market, the choices, and the text of the ten first Google News results for "rapamycin for longevity".
Get Ṁ1,000 play money
Related questions
Related questions
Will anti-aging treatments developed, approved and available for public usage by 2040?
54% chance
What percent of those taking rapamycin to slow aging will comment a positive or neutral review?
56% chance
Will any company successfully develop a therapeutic treatment that rejuvenates healthspan by at least 10 years by 2030?
35% chance
Will a senolytic drug be used clinically to slow, prevent, or reverse aging by the end of 2033?
49% chance
Will Aubrey de Grey's 2022 Robust Mouse Rejuvenation Project "succeed" in its aims of finding an intervention that increases both mean and maximum lifespan of mice by at least 12 months?
34% chance
Will Stephen Wolfram self-report or get in the news 4 any pro-longevity intervention (eg rapamycin/ozempic) by EOY 2028?
32% chance
Will Peter Thiel start regularly taking rapamycin by EOY 2027?
35% chance
Will jurgen schmidhuber end up taking rapamycin by EOY 2028
41% chance
Will we find a way to live forever, i.e. reverse aging and achieve biological immortality by 2046?
30% chance
Will a study performed by the Dog Aging Project show a statistically significant effect of rapamycin on lifespan extension between control groups and a treatment group?
73% chance